110 related articles for article (PubMed ID: 23189554)
1. [Synthesis and anti-tumor properties of myelopeptide MP-1].
Fonina LA; Treshchalina EM; Belevskaia RG; Az'muko AA; Efremov MA; Sedakova LA; Kirilina EA
Bioorg Khim; 2012; 38(4):406-12. PubMed ID: 23189554
[TBL] [Abstract][Full Text] [Related]
2. [Myelopeptide MP-5 and fluorescent derivatives: synthesis and biological activity].
Fonina LA; Az'muko AA; Kalikhevich VN; Levit ML; Ardemasova ZA; Gur'ianov SA; Belevskaia RG; Efremov MA; Treshchalina EM; Mikhaĭlova AA
Bioorg Khim; 2008; 34(4):451-6. PubMed ID: 18695716
[TBL] [Abstract][Full Text] [Related]
3. [Synthesis and properties of the retro-analogue of myelopeptide MP-2].
Fonina LA; Ovchinnikov MV; Gur'ianov SA; Sychev SV; Belevskaia RG; Treshchalina EM
Bioorg Khim; 2005; 31(3):239-44. PubMed ID: 16004381
[TBL] [Abstract][Full Text] [Related]
4. The bone marrow peptide (myelopeptide-2) abolishes induced by human leukemia HL-60 cell suppression of T lymphocytes.
Strelkov LA; Mikhailova AA; Sapozhnikov AM; Fonina LA; Petrov RV
Immunol Lett; 1996 May; 50(3):143-7. PubMed ID: 8803611
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and antitumor properties of an anthraquinone bisubstituted by the copper chelating peptide Gly-Gly-L-His.
Morier-Teissier E; Boitte N; Helbecque N; Bernier JL; Pommery N; Duvalet JL; Fournier C; Hecquet B; Catteau JP; Hénichart JP
J Med Chem; 1993 Jul; 36(15):2084-90. PubMed ID: 8340911
[TBL] [Abstract][Full Text] [Related]
6. Immunoregulatory effects of two bone-marrow hexapeptides (myelopeptides) in experimental models of immunodeficiency.
Mikhailova AA; Shanurin SY; Petrov RV
Immunol Lett; 1995 Sep; 47(3):199-203. PubMed ID: 8747719
[TBL] [Abstract][Full Text] [Related]
7. [A novel immunoregulating hexapeptide with antineoplastic effect].
Treshchalina EM; Sedakova LA; Vlasenkova NK; Zhukova OS; Firsova GA; Mikhaĭlova LM; Kolesnikova EIu; Zimakova NI; Khabarov SV; Gerasimova GK
Vopr Onkol; 2001; 47(3):321-7. PubMed ID: 11544832
[TBL] [Abstract][Full Text] [Related]
8. The Effectiveness of Cyclic Hydroxamic Acid CHA-5 against Drug-Resistant P388 Leukemia Strains.
Goncharova SA; Vystorop IV; Raevskaya TA; Konovalova NP
Bull Exp Biol Med; 2017 Jul; 163(3):385-388. PubMed ID: 28744633
[TBL] [Abstract][Full Text] [Related]
9. Combination effect of navelbine (vinorelbine ditartrate) with cisplatin against murine P388 leukemia and human lung carcinoma xenografts in mice.
Ashizawa T; Asada M; Kobayashi E; Okabe M; Gomi K; Hirata T
Anticancer Drugs; 1993 Oct; 4(5):577-83. PubMed ID: 8292816
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic synergism of tiazofurin and selected antitumor drugs against sensitive and resistant P388 leukemia in mice.
Harrison SD; O'Dwyer PJ; Trader MW
Cancer Res; 1986 Jul; 46(7):3396-400. PubMed ID: 3708573
[TBL] [Abstract][Full Text] [Related]
11. [Synthesis and properties of the myelopeptides with differentiating activity].
Fonina LA; Kudriavtseva EV; Bespalova ZhD; Efremov MA; Mikhaĭlova AA; Kirilina EA
Bioorg Khim; 2010; 36(4):493-7. PubMed ID: 20823917
[TBL] [Abstract][Full Text] [Related]
12. [Effect of the SH-group of myelopeptide MP-3 on its macrophage-stimulating activity].
Fonina LA; Baldin MI; Efremov MA; Gur'ianov SA; Belevskaia RG
Bioorg Khim; 2001; 27(6):403-7. PubMed ID: 11811060
[TBL] [Abstract][Full Text] [Related]
13. Myelopeptide-1 blocks the T-suppressor activity.
Petrov RV; Mikhailova AA; Kirilina EA
Folia Biol (Praha); 1994; 40(6):455-61. PubMed ID: 7589703
[TBL] [Abstract][Full Text] [Related]
14. [Antileukemic activity and development of resistance to cisplatin (CPT) and platinum (IV)-nitroxyl complex VS118].
Goncharova SA; Raevskaia TA; Iakushchenko TN; Blokhina SV; Konovalova NP; Sen' VD
Vopr Onkol; 2011; 57(3):355-8. PubMed ID: 21882607
[TBL] [Abstract][Full Text] [Related]
15. Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia.
Waud WR; Harrison SD; Gilbert KS; Laster WR; Griswold DP
Cancer Chemother Pharmacol; 1991; 27(6):456-63. PubMed ID: 1849465
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effects of pirarubicin and epirubicin in combination with doxifluridine and cisplatin against mouse P388 leukemia.
Agata N; Mase T; Izumi H; Hirano S; Iguchi H; Tone H; Takeuchi T
Cancer Biochem Biophys; 1995 Nov; 15(2):95-101. PubMed ID: 8590441
[TBL] [Abstract][Full Text] [Related]
17. Effect of hyperthermia and X-irradiation on survival and occurrence of metastases in mice bearing P388 tumor.
Perlaky L; Fónagy A; Unger E; Hidvégi EJ
Int J Hyperthermia; 1989; 5(5):603-15. PubMed ID: 2768895
[TBL] [Abstract][Full Text] [Related]
18. [Antineoplastic activity of combinations of cytostatics and dextran-ferrite administered to mice with leukemia P-388].
Brusentsov NA; Glazkova TIu; Iavorskaia NP; Iurchenko NIa
Eksp Onkol; 1990; 12(6):59-60. PubMed ID: 2261881
[TBL] [Abstract][Full Text] [Related]
19. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and antitumor activity of novel dolastatin 10 analogs.
Miyazaki K; Kobayashi M; Natsume T; Gondo M; Mikami T; Sakakibara K; Tsukagoshi S
Chem Pharm Bull (Tokyo); 1995 Oct; 43(10):1706-18. PubMed ID: 8536345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
